A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
NCT05245656
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Mantle Cell Lymphoma
Interventions
DRUG:
RB/RBAC alternating
DRUG:
RB
Sponsor
Kim, Seok Jin